The Prevention Study
Recruitment Closed
21 Sep to 23 Sep 2025
Up to $4,750
Melbourne, Australia
The ongoing battle against COVID-19 has highlighted the need for innovative treatment options, especially for those at higher risk of severe illness. While vaccines and antivirals have provided essential tools, they face limitations, particularly as new variants emerge.
This clinical trial is evaluating a monoclonal antibody treatment designed to target the SARS-CoV-2 spike protein — a key part of the virus that allows it to enter human cells. The investigational therapy is being developed as a potential way to help prevent infection and reduce illness severity, especially in cases of breakthrough infections.
Join our clinical trial
This clinical trial is evaluating a monoclonal antibody treatment designed to target the SARS-CoV-2 spike protein, a key part of the virus that allows it to enter human cells. The investigational therapy is being developed as a potential way to help prevent infection and reduce illness severity, especially in cases of breakthrough infections.
We are conducting this first-in-human (FIH) study to assess the safety, tolerability, and how the body processes the investigational treatment in healthy adult volunteers. This is an important early step in understanding how the therapy behaves in the body before it can be tested in patient populations.
As a FIH study, this trial has been carefully designed with strict safety protocols. Before participating, you will be given detailed information about the study, its procedures, and how risks are managed. You’ll also meet with one of our doctors to discuss any questions you may have.
Why participate?
- Contribute to research that may expand future COVID-19 treatment options — especially for those most at risk.
- Help researchers study a new monoclonal antibody being developed to address gaps in existing therapies.
- Be part of early-stage research that supports the global effort to respond to evolving COVID-19 strains.
Your Role
As a participant, you will receive one dose of the investigational treatment and attend a series of follow-up assessments to monitor how your body responds.
Your involvement helps researchers gather essential data that could inform the next generation of COVID-19 therapies.
Trial details
Study medication
Administered via intravenous (IV) infusion or intramuscular (IM) injection.
Ethics
An independent ethics committee has approved this clinical trial.
Additional eligibility
- Not taking any prescription medication (except for contraception)
- Non-smoker or smoking less than 10 cigarettes per day
Study duration
Approximately 118 days, including screening, 2-night inpatient stay, 7 follow-up visits and 2 follow-up phone calls.
Are you a match?
Age
18 - 65 years old
Remuneration
Up to $4,750 *with screening reimbursement. Please see T&Cs.
Gender
Male or Female
BMI
BMI 19 - 32 kg/m2
Commitment
2 nights, 7 clinic visits
Medical condition
Not taking any medications